Trials / Active Not Recruiting
Active Not RecruitingNCT07202871
A Study of How the Body Absorbs LY3537031
A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3537031 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3537031 in Healthy Participants
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to find out how much LY3537031 gets into the blood stream and how long it takes the body to get rid of it when it is injected just under the skin in different parts of the body, and when it is injected into a vein, in healthy participants. This study will also look at the safety and tolerability of LY3537031.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3537031 | Administered SC |
| DRUG | LY3537031 | Administered IV |
Timeline
- Start date
- 2025-11-03
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2025-10-02
- Last updated
- 2026-01-16
Locations
1 site across 1 country: Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07202871. Inclusion in this directory is not an endorsement.